|Target||Interleukin 17 receptor A|
|Trade names||Siliq, Kyntheum|
|Other names||KHK4827, AMG 827|
|Main uses||Plaque psoriasis|
|Side effects||Joint pain, headache, tiredness, diarrhea, throat pain, nausea, low white blood cells, tinea infections|
|Typical dose||210 mg|
|Chemical and physical data|
|Molar mass||143905.93 g·mol−1|
|(what is this?)|
Brodalumab, sold under the brand name Siliq and Kyntheum, is a medication used to treat plaque psoriasis. Specifically it is used for moderate to severe disease in people who have not improved with other treatments. It is given by injection under the skin.
Common side effects include joint pain, headache, tiredness, diarrhea, throat pain, nausea, low white blood cells, and tinea infections. Other side effects may include infection and Crohn's disease. Safety in pregnancy is unclear. It is a monoclonal antibody which blocks interleukin 17.
Brodalumab was approved for medical use in the United States and Europe in 2017. In the United Kingdom 4 weeks of medication costs the NHS about £1,300 as of 2021. In the United States this amount costs about 2,800 USD.
Mechanism of action
Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. This mechanism is similar to that of another anti-psoriasis antibody, ixekizumab, which however binds to IL-17 itself.
Brodalumab was developed by Amgen, Inc. as AMG 827.
In November 2014, Amgen and AstraZeneca reported encouraging results for the compound. The companies stated that the compound met the primary endpoint showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo.
However, in May 2015, Amgen announced that it was ending its participation in co-development of the compound because of reports of patients having "events of suicidal ideation and behavior". AstraZeneca will be solely responsible for any future development and marketing of brodalumab in all territories except for certain Asian territories such as Japan, where Kyowa Hakko Kirin has rights to brodalumab and continued as KHK4827.
In September 2015, AstraZeneca announced a partnership with Valeant Pharmaceuticals in which Valeant took over exclusive rights to develop and commercialize brodalumab. In July 2016, the rights to commercialize brodalumab in Europe were sold to LEO Pharma.
- "Kyntheum". Retrieved 11 January 2022.
- "DailyMed - SILIQ- brodalumab injection". dailymed.nlm.nih.gov. Retrieved 11 January 2022.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1300. ISBN 978-0857114105.
- "Brodalumab Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 11 January 2022.
- Clinical trial number NCT01708590 for "Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)" at ClinicalTrials.gov
- Clinical trial number NCT01708629 for "Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)" at ClinicalTrials.gov
- Philippidis A (26 November 2014). "Brodalumab's No Turkey in Phase III: Amgen and AstraZeneca". Genetic Engineering & Biotechnology News. Archived from the original on 2014-12-03. Retrieved 2014-11-27.
- "Amgen to terminate participation in co-development and commercialization of brodaluma". Amgen.
- "AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab". www.astrazeneca.com.
- "AstraZeneca enters licensing agreements with LEO Pharma in skin diseases". www.astrazeneca.com.
- House DW (25 January 2016). "FDA accepts AstraZeneca's brodalumab BLA for plaque psoriasis, PDUFA date November 16". Seeking Alpha.
- Office of the Commissioner (15 February 2017). "Press Announcements - FDA approves new psoriasis drug". www.fda.gov. Retrieved 18 February 2017.